Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Celleron Therapeutics

Celleron approached Oxford cancer researchers with an in-licenced HDAC inhibitor asset. Co-investment from our trials unit and local trust in a shared risk scheme was rewarded with significant ROI during the early stage development of CXD101 for advanced cancer. Preliminary efficiency and safety was demonstrated which was used to support >$20M international investment.